Aging may begin in the embryo, and review authors propose looking for ways to slow it in growing animals
Aging may begin in the embryo, and review authors propose looking for ways to slow it in growing animals
On November 12, Vadim Gladyshev of Harvard Medical School and his colleagues published a review of the early origins of aging. They compared molecular estimates of embryonic age with experiments in which a brief intervention during growth altered an animal’s subsequent lifespan.
How do aging germ cells produce a young next generation? In a 2021 study, Gladyshev’s group tracked mouse embryonic development using epigenetic clocks, algorithms that estimate age from chemical marks on DNA. The age estimates initially fell, reaching a minimum around the formation of the three germ layers that give rise to tissues and organs, and then increased. The authors call this minimum “ground zero” and propose that molecular aging begins at this point. In this model, the body develops while age-related changes accumulate.
Researchers can identify periods when an intervention changes later lifespan by suppressing the same gene at different ages. Geneticist Andrew Dillin recalled in a 2010 interview how he came to question the textbook view of continuous aging: “There might be critical periods that govern aging.” He spent a year trying to develop a system for controlling gene activity in worms, but could not get it to work. The solution was to feed the worms bacteria that produced RNA to suppress a selected gene. By changing when the worms received these bacteria, he could test when gene suppression affected lifespan.
A 2022 mouse experiment compared two early-life courses of rapamycin. The drug inhibits mTOR, a protein that coordinates cell growth with nutrient availability. By then, rapamycin had already been shown to extend lifespan in adult mice. In one group, the drug was given only from day 4 to day 30 of life and then withdrawn. With males and females analyzed together, median lifespan, the age to which half the animals survived, increased from 697 days in untreated mice to 764 days, a gain of 9,6%.
Treatment from day 30 to day 60 produced no significant increase in lifespan. To check the drug’s activity, the researchers measured mTOR inhibition in the liver after the first four days of each course and found comparable levels. In this experiment, only the course that began earlier extended lifespan after treatment ended.
Mice given the earlier course remained smaller than controls even as adults. In a separate experiment in Gladyshev’s laboratory, mice received rapamycin from birth to day 45 and had their first litters later than control animals. Growth signals are needed for organ formation, maturation, and reproduction. Suppressing these signals to extend lifespan also changes how the animal develops. Development also brings beneficial traits, such as cellular resistance to adverse conditions. The review authors propose looking for interventions that reduce the accumulation of damage while preserving these beneficial changes.
A short course of treatment needs to be evaluated over the animal’s remaining lifetime: how it grew, whether it retained the ability to reproduce, and how long it lived after treatment ended.